BACKGROUND: Multiple myeloma is usually fatal due to serial relapses that become progressively refractory to therapy. CD19 is typically absent on the dominant multiple myeloma cell population but may be present on minor subsets with unique myeloma-propagating properties. To target myeloma-propagating cells, we clinically evaluated autologous T cells transduced with a chimeric antigen receptor (CAR) against CD19 (CTL019). METHODS: Subjects received CTL019 following salvage high-dose melphalan and autologous stem cell transplantation (ASCT). All subjects had relapsed/refractory multiple myeloma and had previously undergone ASCT with less than 1 year progression-free survival (PFS). RESULTS: ASCT + CTL019 was safe and feasible, with most toxicity attributable to ASCT and no severe cytokine release syndrome. Two of 10 subjects exhibited significantly longer PFS after ASCT + CTL019 compared with prior ASCT (479 vs. 181 days; 249 vs. 127 days). Correlates of favorable clinical outcome included peak CTL019 frequency in bone marrow and emergence of humoral and cellular immune responses against the stem-cell antigen Sox2. Ex vivo treatment of primary myeloma samples with a combination of CTL019 and CAR T cells against the plasma cell antigen BCMA reliably inhibited myeloma colony formation in vitro, whereas treatment with either CAR alone inhibited colony formation inconsistently. CONCLUSION: CTL019 may improve duration of response to standard multiple myeloma therapies by targeting and precipitating secondary immune responses against myeloma-propagating cells. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02135406. FUNDING: Novartis, NIH, Conquer Cancer Foundation.
BACKGROUND:Multiple myeloma is usually fatal due to serial relapses that become progressively refractory to therapy. CD19 is typically absent on the dominant multiple myeloma cell population but may be present on minor subsets with unique myeloma-propagating properties. To target myeloma-propagating cells, we clinically evaluated autologous T cells transduced with a chimeric antigen receptor (CAR) against CD19 (CTL019). METHODS: Subjects received CTL019 following salvage high-dose melphalan and autologous stem cell transplantation (ASCT). All subjects had relapsed/refractory multiple myeloma and had previously undergone ASCT with less than 1 year progression-free survival (PFS). RESULTS: ASCT + CTL019 was safe and feasible, with most toxicity attributable to ASCT and no severe cytokine release syndrome. Two of 10 subjects exhibited significantly longer PFS after ASCT + CTL019 compared with prior ASCT (479 vs. 181 days; 249 vs. 127 days). Correlates of favorable clinical outcome included peak CTL019 frequency in bone marrow and emergence of humoral and cellular immune responses against the stem-cell antigen Sox2. Ex vivo treatment of primary myeloma samples with a combination of CTL019 and CAR T cells against the plasma cell antigen BCMA reliably inhibited myeloma colony formation in vitro, whereas treatment with either CAR alone inhibited colony formation inconsistently. CONCLUSION: CTL019 may improve duration of response to standard multiple myeloma therapies by targeting and precipitating secondary immune responses against myeloma-propagating cells. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02135406. FUNDING: Novartis, NIH, Conquer Cancer Foundation.
Entities:
Keywords:
Cancer immunotherapy; Hematology; Oncology
Authors: Laurie A Boyer; Tong Ihn Lee; Megan F Cole; Sarah E Johnstone; Stuart S Levine; Jacob P Zucker; Matthew G Guenther; Roshan M Kumar; Heather L Murray; Richard G Jenner; David K Gifford; Douglas A Melton; Rudolf Jaenisch; Richard A Young Journal: Cell Date: 2005-09-23 Impact factor: 41.582
Authors: Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp Journal: N Engl J Med Date: 2014-10-16 Impact factor: 91.245
Authors: Laura C Michaelis; Ayman Saad; Xiaobo Zhong; Jennifer Le-Rademacher; Cesar O Freytes; David I Marks; Hillard M Lazarus; Jennifer M Bird; Leona Holmberg; Rammurti T Kamble; Shaji Kumar; Michael Lill; Kenneth R Meehan; Wael Saber; Jeffrey Schriber; Jason Tay; Dan T Vogl; Baldeep Wirk; Bipin N Savani; Robert P Gale; David H Vesole; Gary J Schiller; Muneer Abidi; Kenneth C Anderson; Taiga Nishihori; Matt E Kalaycio; Julie M Vose; Jan S Moreb; William Drobyski; Reinhold Munker; Vivek Roy; Armin Ghobadi; H Kent Holland; Rajneesh Nath; L Bik To; Angelo Maiolino; Adetola A Kassim; Sergio A Giralt; Heather Landau; Harry C Schouten; Richard T Maziarz; Joseph Mikhael; Tamila Kindwall-Keller; Patrick J Stiff; John Gibson; Sagar Lonial; Amrita Krishnan; Angela Dispenzieri; Parameswaran Hari Journal: Biol Blood Marrow Transplant Date: 2013-01-05 Impact factor: 5.742
Authors: Edward A Stadtmauer; Dan T Vogl; Eline Luning Prak; Jean Boyer; Nicole A Aqui; Aaron P Rapoport; Kenyetta R McDonald; Xiaoling Hou; Heather Murphy; Rita Bhagat; Patricia A Mangan; Anne Chew; Elizabeth A Veloso; Bruce L Levine; Robert H Vonderheide; Abbas F Jawad; Carl H June; Kathleen E Sullivan Journal: Blood Date: 2010-09-23 Impact factor: 22.113
Authors: Kelly Boucher; Nancy Parquet; Raymond Widen; Kenneth Shain; Rachid Baz; Melissa Alsina; John Koomen; Claudio Anasetti; William Dalton; Lia E Perez Journal: Clin Cancer Res Date: 2012-09-17 Impact factor: 12.531
Authors: Sebastian Kobold; Sinje Tams; Tim Luetkens; Yanran Cao; Orhan Sezer; Britta Marlen Bartels; Henrike Reinhard; Julia Templin; Katrin Bartels; York Hildebrandt; Nesrine Lajmi; Andreas Marx; Friedrich Haag; Carsten Bokemeyer; Nicolaus Kröger; Djordje Atanackovic Journal: Clin Dev Immunol Date: 2011-11-15
Authors: Adam D Cohen; Alfred L Garfall; Edward A Stadtmauer; J Joseph Melenhorst; Simon F Lacey; Eric Lancaster; Dan T Vogl; Brendan M Weiss; Karen Dengel; Annemarie Nelson; Gabriela Plesa; Fang Chen; Megan M Davis; Wei-Ting Hwang; Regina M Young; Jennifer L Brogdon; Randi Isaacs; Iulian Pruteanu-Malinici; Don L Siegel; Bruce L Levine; Carl H June; Michael C Milone Journal: J Clin Invest Date: 2019-03-21 Impact factor: 14.808
Authors: January Salas-Mckee; Weimin Kong; Whitney L Gladney; Julie K Jadlowsky; Gabriela Plesa; Megan M Davis; Joseph A Fraietta Journal: Hum Vaccin Immunother Date: 2019-04-02 Impact factor: 3.452
Authors: Adam D Cohen; Noopur Raje; Jessica A Fowler; Khalid Mezzi; Emma C Scott; Madhav V Dhodapkar Journal: Clin Cancer Res Date: 2019-10-31 Impact factor: 12.531